Solid Biosciences Inc. (SLDB) — Financial statements
Income statement, balance sheet, and cash flow for Solid Biosciences Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 8↓40.6% | 14 | |
| Cost of Revenue | 2↓33.4% | 2↓4.9% | 3 | 0.00 | 0.00 | |
| Gross Profit | -2↑33.4% | -2↑4.9% | -3↓131.9% | 8↓40.6% | 14 | |
| Operating Expenses | ||||||
| R&D Expenses | 140↑45.5% | 96↑25.9% | 77↓2.4% | 78↑33.5% | 59 | |
| General & Administrative Expenses | 39↑16.8% | 33↑20.0% | 28↓4.1% | 29↑6.7% | 27 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 39↑16.8% | 33↑20.0% | 28↓4.1% | 29↑6.7% | 27 | |
| Other Expenses | -2↑33.4% | -2↑4.9% | -3↓136.0% | 7 | 0.00 | |
| Operating Expenses | 178↑39.5% | 127↑25.1% | 102↓11.2% | 115↑33.4% | 86 | |
| Total Costs & Expenses | 179↑38.1% | 130↑24.4% | 104↓8.9% | 115↑33.4% | 86 | |
| Operating Results | ||||||
| Operating Income | -179↓38.1% | -130↓24.4% | -104↑2.0% | -106↓47.3% | -72 | |
| Depreciation & Amortization | 2↓33.4% | 2↓4.9% | 3↑7.2% | 2↓18.8% | 3 | |
| EBITDA | -178↓45.7% | -122↓30.5% | -93↑3.5% | -97↓39.8% | -69 | |
| EBIT | -179↓44.1% | -124↓29.5% | -96↑3.3% | -99↓37.4% | -72 | |
| Interest & Other Income | ||||||
| Net Interest Income | 10↑8.5% | 9↑27.8% | 7↑173.0% | 3↑3987.5% | 0.06 | |
| Interest Income | 10↑4.6% | 9↑32.6% | 7↑173.0% | 3↑3987.5% | 0.06 | |
| Interest Expense | 0.00↓100.0% | 0.34 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -5↑35.3% | -8↓15.6% | -7 | 0.00 | |
| Other Income / Expenses | 5↓3.0% | 5↓39.4% | 8↓59.5% | 20↑30916.7% | 0.07 | |
| Income Before Tax | -174↓39.8% | -125↓29.9% | -96↓11.7% | -86↓19.1% | -72 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -174↓39.8% | -125↓29.9% | -96↓11.7% | -86↓19.1% | -72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -174↓39.8% | -125↓29.9% | -96↓11.7% | -86↓19.1% | -72 | |
| Bottom-Line Net Income | -174↓39.8% | -125↓29.9% | -96↓11.7% | -86↓19.1% | -72 | |
| EPS (Basic) | -1.99↑35.0% | -3.06↑36.6% | -4.83↑52.2% | -10.10↑0.4% | -10.14 | |
| EPS (Diluted) | -1.99↑35.0% | -3.06↑36.6% | -4.83↑52.2% | -10.10↑0.4% | -10.14 | |
| Weighted Average Shares | 88↑114.4% | 41↑105.3% | 20↑133.6% | 9↑19.6% | 7 | |
| Weighted Average Diluted Shares | 88↑114.4% | 41↑105.3% | 20↑133.6% | 9↑19.6% | 7 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.